A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK- 7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies
Primary Objective
Part 1: To determine the safety and tolerability of MK-7684A (Cohorts A to F)
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Steven Bair, MD
Study ID
Protocol Number: 21-4054
More information available at ClinicalTrials.gov: NCT05005442
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers